Evidence map›Paper›PMID 40707948›Full record

ReviewJournal of translational medicine2025

Unlocking the mitochondrial functional code: unraveling the pathogenesis of ovarian cancer and innovative targets to inhibit malignant behavior.

Chen-Yu Li, Dan-Ni Ding, Ying Guo, Yang Fu, Ying Shen, Jiang-Mei Fu, Cheng-Xin Zhang, Feng-Juan Han

Abstract readReview
In one paragraph

Review in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Chen-Yu LiDepartment of Obstetrics and Gynecology, Heilongjiang University of Chinese Medicine, Harbin, 150040, Heilongjiang, China.ORCID 0000-0001-5428-4684
Dan-Ni DingDepartment of Obstetrics and Gynecology, Heilongjiang University of Chinese Medicine, Harbin, 150040, Heilongjiang, China.
Ying GuoDepartment of Obstetrics and Gynecology, The First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, 150040, Heilongjiang, China.
Yang FuDepartment of Obstetrics and Gynecology, The First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, 150040, Heilongjiang, China.
Ying ShenDepartment of Obstetrics and Gynecology, The First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, 150040, Heilongjiang, China.
Jiang-Mei FuDepartment of Vascular Surgery, Wenshang County Traditional Chinese Medicine Hospital, Jining, 272000, Shandong, China.
Cheng-Xin ZhangDepartment of Preventive Medicine, Wenshang County Traditional Chinese Medicine Hospital, Jining, 272000, Shandong, China.
Feng-Juan HanDepartment of Obstetrics and Gynecology, The First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, 150040, Heilongjiang, China. hanfengjuan2004@163.com.ORCID 0000-0002-5953-3608

Funding

National Natural Science Foundation of China 82274566
6 · The paper itself

Abstract

This article focuses on ovarian cancer (OC), the most lethal gynecological malignancy, whose risk is influenced by multiple factors, including genetic background, age, reproductive history, parity, obesity status, and smoking habits. Mitochondria, as the core organelles in eukaryotic cells, play a pivotal role in the initiation and progression of OC. In recent years, growing evidence has revealed a close relationship between mitochondrial dysfunction and the accelerated proliferation, enhanced invasiveness, metastasis ability, and therapy resistance of OC. This paper provides an in-depth analysis of the complex interactions between mitochondrial dysfunction and the malignant biological characteristics of OC, as well as the underlying regulatory mechanisms of mitochondrial function. Furthermore, it elaborates on how genetic variations, regulatory factors, and the tumor microenvironment (TME) influence mitochondrial function and drive the malignant progression of OC. Additionally, this paper comprehensively summarizes therapeutic strategies targeting mitochondrial dysfunction in OC, aiming to provide novel insights and strategies for clinical research and treatment.

Indexed as

MitochondriaMolecular Targeted TherapyOvarian NeoplasmsAnimalsFemaleHumansTumor MicroenvironmentCancer therapyMalignant biological behaviorMitochondrial dysfunctionOCPathogenesis

Identifiers

PMID40707948
PMCPMC12291528

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.